Comparison of lead failure manifestation of Biotronik Linox with St. Jude Medical Riata and Medtronic Sprint Fidelis lead

  • Anna Lam
  • Stefan Buehler
  • Eleni Goulouti
  • Romy Sweda
  • Andreas Haeberlin
  • Argelia Medeiros-Domingo
  • Helge Servatius
  • Jens Seiler
  • Samuel Baldinger
  • Fabian Noti
  • Hildegard Tanner
  • Laurent RotenEmail author



To compare lead failure manifestation and lead performance of the Biotronik Linox/Sorin Vigila defibrillator lead (Linox group) with the St. Jude Medical Riata/Riata ST (Riata group) and Medtronic Sprint Fidelis defibrillator leads (Fidelis group).


We assessed the performance of all aforementioned leads implanted at our center and investigated the manifestation of lead failures.


Of 93 Linox, 86 Riata, and 81 Fidelis leads implanted at our center, 11 (12%), 22 (26%), and 25 (31%) leads failed during a median follow-up of 46, 61, and 84 months, respectively. Inappropriate shocks were delivered in 64% (Linox), 5% (Riata), and 32% (Fidelis) of lead failures; a device alert was noted in none (Linox), 5% (Riata), and 52% (Fidelis); and lead failure was a coincidental finding in 36% (Linox), 91% (Riata), and 16% (Fidelis) of cases (p < 0.001). Non-physiological high rate signals were observed in 73% (Linox), 27% (Riata), and 80% (Fidelis) of lead failures (p = 0.001) and damaged lead integrity was found in 36% (Linox), 73% (Riata), and 24% (Fidelis) of cases (p = 0.064). Lead survival at 5 years was 88%, 92%, and 71% for Linox, Riata, and Fidelis group, respectively.


The most frequent clinical manifestation of lead failure was inappropriate shocks for Linox, coincidental finding for Riata and device alert for Fidelis leads. Non-physiological high rate signals were frequently observed in Linox and Fidelis lead failures whereas in Riata lead failures, a damaged lead integrity was the predominant finding.


Defibrillator lead Lead failure Linox Riata Sprint fidelis 



Cardiac resynchronization therapy


Sprint Fidelis


Implantable cardioverter defibrillator




Riata/Riata ST


St. Jude Medical



We would like to thank Dik Heg for the assistance in the statistical analysis of this study.

Compliance with ethical standards

The study was conducted in accordance with the local institutional committee on human research and national regulatory authorities.

Conflict of interest

A. Lam received an educational grant from the “Swiss Heart Rhythm Foundation” for a fellowship at the Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux-Pessac, France. A. Haeberlin has received travel and educational support from Medtronic. A. Medeiros-Domingo has received travel support from Amgen. J. Seiler has received travel educational support from Biosense Webster and his spouse is an employee of Boston Scientific. S. Baldinger has received travel support from LivaNova. L. Roten has received travel support from Biosense Webster and Boston Scientific. St. Buehler, E. Goulouti, R. Sweda, F. Noti, H. Servatius, and H. Tanner have no disclosures.

Supplementary material

10840_2018_486_Fig2_ESM.png (1.6 mb)
Supplementary Figure 1

Updated flow chart of lead status of our Linox/Vigila lead population with regard to our original publication.12 Lead failures that occurred additionally since our original publication are highlighted (dark red). (PNG 1612 kb)

10840_2018_486_MOESM1_ESM.tif (127 kb)
High resolution image (TIF 127 kb)


  1. 1.
    Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2007;4:892–6.CrossRefGoogle Scholar
  2. 2.
    Sung RK, Massie BM, Varosy PD, Moore H, Rumsfeld J, Lee BK, et al. Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience. Heart Rhythm. 2012;9:1954–61.CrossRefGoogle Scholar
  3. 3.
    Hauser RG, Maisel WH, Friedman PA, Kallinen LM, Mugglin AS, Kumar K, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for patient management. Circulation. 2011;123:358–63.CrossRefGoogle Scholar
  4. 4.
    Abdelhadi RH, Saba SF, Ellis CR, Mason PK, Kramer DB, Friedman PA, et al. Independent multicenter study of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm. 2013;10:361–5.CrossRefGoogle Scholar
  5. 5.
    Swerdlow CD, Kalahasty G, Ellenbogen KA. Implantable cardiac defibrillator lead failure and management. J Am Coll Cardiol. 2016;67:1358–68.CrossRefGoogle Scholar
  6. 6.
    Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2016;13:e50–86.CrossRefGoogle Scholar
  7. 7.
    Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Stadler RW, Gillberg JM, et al. Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads. Circulation. 2008;118:2122–9.CrossRefGoogle Scholar
  8. 8.
    Koneru JN, Kaszala K, Bordachar P, Shehata M, Swerdlow C, Ellenbogen KA. Spectrum of issues detected by an ICD diagnostic alert that utilizes far-field electrograms: clinical implications. Heart Rhythm. 2015;12:957–67.CrossRefGoogle Scholar
  9. 9.
    Good ED, Cakulev I, Orlov MV, Hirsh D, Simeles J, Mohr K, et al. Long-term evaluation of Biotronik Linox and Linox(smart) implantable cardioverter defibrillator leads. J Cardiovasc Electrophysiol. 2016;27:735–42.CrossRefGoogle Scholar
  10. 10.
    van Malderen SC, Szili-Torok T, Yap SC, Hoeks SE, Zijlstra F, Theuns DA. Comparative study of the failure rates among 3 implantable defibrillator leads. Heart Rhythm. 2016.Google Scholar
  11. 11.
    Padfield GJ, Steinberg C, Karim SS, Tung S, Bennett MT, Le Maitre JP, et al. Early failure of the Biotronik Linox implantable cardioverter defibrillator lead. J Cardiovasc Electrophysiol. 2015;26:274–81.CrossRefGoogle Scholar
  12. 12.
    Noti F, Lam A, Klossner N, Seiler J, Servatius H, Medeiros-Domingo A, et al. Failure rate and conductor externalization in the Biotronik Linox/Sorin Vigila implantable cardioverter-defibrillator lead. Heart Rhythm. 2016;13:1075–82.CrossRefGoogle Scholar
  13. 13.
    Kawada S, Nishii N, Morimoto Y, Miyoshi A, Tachibana M, Sugiyama H, et al. Comparison of longevity and clinical outcomes of implantable cardioverter-defibrillator leads among manufacturers. Heart Rhythm. 2017;14:1496–503.CrossRefGoogle Scholar
  14. 14.
    Schmutz M, Delacretaz E, Schwick N, Roten L, Fuhrer J, Boesch C, et al. Prevalence of asymptomatic and electrically undetectable intracardiac inside-out abrasion in silicon-coated Riata(R) and Riata(R) ST implantable cardioverter-defibrillator leads. Int J Cardiol. 2013;167:254–7.CrossRefGoogle Scholar
  15. 15.
    Kallinen LM, Hauser RG, Tang C, Melby DP, Almquist AK, Katsiyiannis WT, et al. Lead integrity alert algorithm decreases inappropriate shocks in patients who have Sprint Fidelis pace-sense conductor fractures. Heart Rhythm. 2010;7:1048–55.CrossRefGoogle Scholar
  16. 16.
    Fazal IA, Shepherd EJ, Tynan M, Plummer CJ, McComb JM. Comparison of Sprint Fidelis and Riata defibrillator lead failure rates. Int J Cardiol. 2013;168:848–52.CrossRefGoogle Scholar
  17. 17.
    Parkash R, Thibault B, Mangat I, Coutu B, Bennett M, Healey J, et al. Canadian registry of implantable electronic device outcomes: surveillance of the Riata lead under advisory. Circ Arrhythm Electrophysiol. 2016;9.Google Scholar
  18. 18.
    Liu J, Rattan R, Adelstein E, Barrington W, Bazaz R, Brode S, et al. Fluoroscopic screening of asymptomatic patients implanted with the recalled Riata lead family. Circ Arrhythm Electrophysiol. 2012;5:809–14.CrossRefGoogle Scholar
  19. 19.
    Steinberg C, Padfield GJ, Hahn E, Flavelle S, Mc IC, O VANB, et al. Lead integrity alert is useful for assessment of performance of Biotronik Linox leads. J Cardiovasc Electrophysiol. 2015;26:1340–5.CrossRefGoogle Scholar
  20. 20.
    Parkash R, Tung S, Champagne J, Healey JS, Thibault B, Cameron D, et al. Insight into the mechanism of failure of the Riata lead under advisory. Heart Rhythm. 2015;12:574–9.CrossRefGoogle Scholar
  21. 21.
    Slotwiner D, Varma N, Akar JG, Annas G, Beardsall M, Fogel RI, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm. 2015;12:e69–95.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Anna Lam
    • 1
    • 2
  • Stefan Buehler
    • 1
  • Eleni Goulouti
    • 1
  • Romy Sweda
    • 1
    • 3
  • Andreas Haeberlin
    • 1
    • 3
  • Argelia Medeiros-Domingo
    • 1
  • Helge Servatius
    • 1
  • Jens Seiler
    • 1
  • Samuel Baldinger
    • 1
  • Fabian Noti
    • 1
  • Hildegard Tanner
    • 1
  • Laurent Roten
    • 1
    Email author
  1. 1.Department of Cardiology, Inselspital, Bern University HospitalUniversity of BernBernSwitzerland
  2. 2.Electrophysiology and Ablation Unit, Bordeaux University Hospital (CHU) and IHU Liryc, Electrophysiology and Heart Modeling InstituteFondation Bordeaux UniversityBordeauxFrance
  3. 3.ARTORG Center for Biomedical EngineeringUniversity of BernBernSwitzerland

Personalised recommendations